The damage oxidative in liver and kidney rat is attenuated across rhe modulation of the CYP2E1 by the consumption of red vine
Abstract
Antecedentes: El vino protege contra patologias crónicas, gracias a sus propiedades antioxidantes. Sin embargo, la metabolización del etanol realizada en parte por la CYP 2E1 hepática, genera especies reactivas de oxígeno (EROS). El objetivo fue determinar si el consumo de vino atenúa la inducción de la isoenzima CYP 2E1 por etanol en hígado y riñon.
Materiales y método: Ratas fueron tratadas con agua, etanol, vino tinto o vino tinto desalcoholizado por 10 semanas. El contenido de CYP total, CYP 2E1 fue evaluado en la fracción microsomal hepática y renal, y su actividad mediante la oxidación de etanol y p-nitrofenol.
Resultados: El etanol aumentó el CYP total y CYP 2E1, así como la hidroxilación de p-nitrofenol y la oxidación de etanol en ambos ´órganos, efectos atenuados por la administración de vino.
Conclusiones: Los componentes no alcohólicos del vino atenúan la inducción de actividad de CYP 2E1 y el daño oxidativo por EROS que provoca el etanol sobre hígado y riñón de rata.
Keywords:
citocromo P450, etanol, estrés oxidativo, hígado, rinónReferences
(1) Paller MS, Weber K, Patten M. Nitric oxide mediated renal epithelial cell injury during hypoxia and reoxygenation. Ren. Fail. 20; 459-469: 1998.
(2) Barrouillet MP, Moiret A, Cambar J. Protective effects of polyphenols against cadmium-induced glomerular mesangial cell myocontracture. Arch. Toxicol. 73; 485-488: 1999.
(3) Zager RA, Burkhart K. Myoglobin in proximal human kidney cells: roles of Fe, Ca2+, H202. A mitochondrial electron transport. Kidney Int. 51; 728-738: 1997.
(4) Klabr S. Urinary tract obstruction. Semin. Nephrol. 21; 133-145: 2001.
(5) Greiber S, Kramer-Guth A, Pavenstadt H, Gutenskunt M, Schollmeyer P, Wanner C. Effects of lipoprotein(a) on mesangial cell proliferation and viability. Nephrol. Dial. Transplant. 11; 778-785: 1996.
(6) Kitamura M, Ishikawa Y. Oxidant-induced apoptosis of glomerular cells: intracellular signaling and its intervention by bioflavonoid. Kidney Int. 56; 1223-1229: 1999.
(7) Fryer MJ. Vitamin E may slow kidney failure owing to oxidative stress. Redox. Rep. 3; 259-61: 1997.
(8) Orellana M, Valdés E, Fernández J, Rodrigo R (1998). Effects of chronic ethanol consumtion on extramitochondrial fatty acid oxidation and ethanol metabolism by rat kidney. Gen. Pharmacol. 30; 719-723.
(9) Rodrigo R, Rivera G. 2002. Renal damage mediated dy oxidative stress: a hypotesis of protective effects of red wine. Free Radical Biology and medicine. Vol 33 N°2 (en prensa).
(10) Duthie GG, Pedersen MW, Gardner PT, Morrice PC, Jenkinson AM, McPhail DB and Steele GM. (1998) The effect of whisky and wine consumption on total phenol content and antioxidant capacity of plasma from healthy volunteers. European Journal of Clinical Nutrition 52, 733-736.
(11) Serafini M, Malani G, and Ferro-Luzzi A (1998) Alcohol-free red wine enhances plasma antioxidant capacity in humans. J. Nutr. 128, 1003-1007.
(12) Roig R, Cascón E, Arola L, Bladé C, and Salvadó MJ. (1999) Moderate red wine consumption protects against oxidation in vivo. Life Sci 64, 1517-1524.
(13) Sveglati B, Jezequiel AM, Orlandi F. (1999). Wine: risk factors for liver disease and antifibrotic compounds. Drugs Exp. Clin. Res 25, 143-145.
(14) Lavy A, Fuhrman B, Markel A, Danker G, Ben-Amotz A, Presser D, & Aviram M. (1994) Effect of dictary supplementation of red or white wine on human blood chemistry, haematology and coagulation: favourable effect of red wine on plasma high-density lipoprotein. Ann. Nutr. Metab. 38: 287-294.
(15) Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B. (1993) Moderate alcohol intake, increased levels of highdensity lipoprotein and its sub fractions, and decreased risk of myocardial infarction. N. Engl. J. Med. 329; 1829-33.
(16) Rimm EB, Givannucci EL, Willet WC, Colditz GA, Ascherio A, Rosner B. (1991) Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 338; 464-86.
(17) Renaud S. & de Lorgeril M. (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339; 1523-1526.
(18) Guivernau M, Baraona E, Soong J, & Lieber CS. (1989) Enhanced stimulatory effect of high density lipoproteins (HDL) and other agonists on vascular prostacyclin production in rats fed alcohol-containing diets. Bichem. Pharmacol. 38; 503-508.
(19) Situyanake R, Crump BJ, Thurnham DL, Davies JA, Gearty J, & Davis M. (1990) Lipid peroxidation and hepatic antioxidants in alcoholic liver disease. Gut 31; 1311-17.
(20) Videla LA, & Valenzuela A. (1982) Alcohol ingestion, liver elutathione and lipoperoxidation: metabolic interrelation and pathological implications. Life Sci. 31; 2395-2407.
(21) Ronis MJJ, Huang J, Crouch J, Mercado C, Irby D, Valentine CR, Lumpkin CK, Ingelmen-Sundberg M, and Badger TMJ. (1993) Cytochrome P450 CYP2EI induction during alcohol exposure occurs by a two-step mechanism associated with blood alcohol concentrations in rats. J Pharm Exp Ther. 264; 944-950.
(22) Licher CS. (1999) Microsomal ethanol-oxidizing system (MEOS): The first 30 years (1968-1998). Alcoholism: Clinical and Experimental Research 23; 991-1007.
(23) Philpot RM. (1991) Characterization of cytochrome P450 in extrahepatic tissues. In Methods in Enzimology. Cytochrome P450. Waterman and Johnson EF, Eds Vol 206 pp 623-631. New York. Academic press.
(24) Amet Y, Berthou F, Goasdulff T, Salaun JP, Le Berton L, Menez JF. (1994). Evidence that cytochrome P450 2E1 is involved in the (w1)-hydroxylation of laurie acid in rat liver microsomes. Biochem. Res. Commun. 203; 1168-1174.
(25) Hirohide A, Imaoka S, Kuroki T, Monna T, Funnae Y. (1996). Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s. J Pharmacol. Exp. Ther. 277; 1004-1009.
(26) Lieber CS. (1997) Cytochrome P450 2E1: its physiological and pathological role. Physiological Reviews. 77; 517-544.
(27) Halliwell B, Hu ML, Louie S, et al. (1992). Interaction of nitrogen dioxide with human plasma. Antioxidant depletion and oxidative damage. FEBS Lett. 16; 62-66.
(28) Baliga R, Ueda N, Walker RR, and Shah SV. (1997) Oxidant mechanisms in toxic acute renal failure. American Journal of Kidney Diseases 29; 465-477.
(29) Fryer MJ. 1997. Vitamin E may slow kidney failure owing to oxidative stress. Redox Rep. 3; 259-261.
(30) Benzie IFF, and Strain JJ. (1996) The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: The FRAP assay. Analytical Biochemistry. 239; 70-76.
(31) Brink N, Bonnichsen R, and Theorell H. (1954). A modified method for the enzymatic microdetermination of ethanol. Acta Pharmacol. Toxicol. 10; 223-226.
(32) Orellana M, Fuentes O, Rosenbluth H, Lara M, and Valdés E. (1992) Modulation of rat liver peroxisomal and microsomal fatty acid oxidation by starvation. FEBS Lett. 310; 193-196.
(33) Lowry OH, Rosebrought NJ, Farr AL, and Randall RJ. (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193; 265-275.
(34) Omura T, Sato R. (1964). The carbon monoxide-binding pigment by liver microsomes. J. Biol. Chem. 239; 2379-2385.
(35) Reinke LA, and Moyer MJ. (1985) p-Nitrophenol hydroxylation. A microsomal oxidation wich is highly inducible by ethanol. Drug. Metab. Dispos. 13; 548-552.
(36) Handler JA, Bradford BU, Glassman E, Ladine JK, Thurman RG. (1986). Catalase-dependent ethanol metabolism in vivo in deermice lacking alcohol dehydrogenase. Biochem. Pharmacol. 35; 4487-4492.
(37) Towbin H, Stahelim T, and Gordon J. (1979) Electroforetic transfer of proteins from polyacrilamide gels to nitrocellulose sheets. Procedure and some applications. Proc. Natl. acad. Sci. USA 76; 4350-4355.
(38) Kera Y, Ohbora Y, Komura S. (1988) The metabolism of acetaldehyde and not acetaldehyde itself is responsible for in vivo ethanol-induced lipid peroxidation in rats. Biochem. Pharmacol. 37; 3633-3638.
(39) Lieber CS. (1996) Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver disease. In: Advances in Pharmacol. Vol. 38; 601-628.
(40) Cecchin E, and De Marchi S. (1996). Alcohol misuse and renal damage. Addiction Biol. 1; 7-17.
(41) Lucas DC, Menez C, Girre P, Bodenez E, Hispard, and JF Menez. Decrease in cytochrome p-4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol. Clin. Exp. Res. 19; 362-366, 1995.
(42) Chan WK, Nguyen LT, Miller VP, Harris RZ. (1998) Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci. 62; 135-142.
(43) Chun YJ, Kim MY, Guengerich FP. (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun. 262; 20-24.
(44) Salazar DE, CL Sorge, and GB Corcoran. Obesity as risk factor for drug-inducing organ injury. VI. Increased hepatic P-450 concentration and microsomal ethanol oxidizing activity bin the obese overfed rat. Bichem. Biophys. Res. Commun. 157; 315-320, 1988.
(45) Bellward GD, T Chang, JH Rodríguez, JH McNeil, S Maines, DE Ryan, W Levin, and PE Thomas. Hepatic cytochrome P-450 induction in the spontancously diabetic BB rat. Mol. Pharmacol. 33; 140-143, 1987.
(46) Giovaninni L, Miglioni M, Longoni BM, Dast DK, Verteli AA, Panichi V. Resveratrol, a Polyphenol found in wine, reduces ischemia reperfusion injury in rat kindney. J Cardiovas Pharmacol 2001 Mar 37(3); 262-70.
(47) Bertelli A, Panichi V, Fillipi C, Bertelli A. (2001) Reservation apolyphenol found in wine: reduces ischemia reperfusión injury in rat kidney. J. Cardiovas Pharmacol. Vol 37; 267-270.
